全文获取类型
收费全文 | 1438433篇 |
免费 | 128492篇 |
国内免费 | 4265篇 |
专业分类
耳鼻咽喉 | 23440篇 |
儿科学 | 50100篇 |
妇产科学 | 37698篇 |
基础医学 | 188026篇 |
口腔科学 | 35434篇 |
临床医学 | 138220篇 |
内科学 | 305731篇 |
皮肤病学 | 35607篇 |
神经病学 | 116041篇 |
特种医学 | 57697篇 |
外国民族医学 | 660篇 |
外科学 | 236824篇 |
综合类 | 27819篇 |
现状与发展 | 73篇 |
一般理论 | 396篇 |
预防医学 | 104239篇 |
眼科学 | 31438篇 |
药学 | 96949篇 |
2篇 | |
中国医学 | 2440篇 |
肿瘤学 | 82356篇 |
出版年
2021年 | 10991篇 |
2019年 | 11332篇 |
2018年 | 20172篇 |
2017年 | 16894篇 |
2016年 | 18845篇 |
2015年 | 20345篇 |
2014年 | 31889篇 |
2013年 | 41294篇 |
2012年 | 41945篇 |
2011年 | 44086篇 |
2010年 | 32882篇 |
2009年 | 35548篇 |
2008年 | 42928篇 |
2007年 | 43953篇 |
2006年 | 46528篇 |
2005年 | 42977篇 |
2004年 | 41454篇 |
2003年 | 39305篇 |
2002年 | 38706篇 |
2001年 | 67982篇 |
2000年 | 69803篇 |
1999年 | 59806篇 |
1998年 | 18769篇 |
1997年 | 17169篇 |
1996年 | 17446篇 |
1995年 | 16550篇 |
1994年 | 14707篇 |
1993年 | 13368篇 |
1992年 | 46222篇 |
1991年 | 45148篇 |
1990年 | 43574篇 |
1989年 | 41591篇 |
1988年 | 38133篇 |
1987年 | 37350篇 |
1986年 | 34812篇 |
1985年 | 33321篇 |
1984年 | 24946篇 |
1983年 | 21062篇 |
1982年 | 12422篇 |
1981年 | 11285篇 |
1979年 | 21897篇 |
1978年 | 15365篇 |
1977年 | 13080篇 |
1976年 | 12132篇 |
1975年 | 13103篇 |
1974年 | 15070篇 |
1973年 | 14529篇 |
1972年 | 13373篇 |
1971年 | 12060篇 |
1970年 | 11432篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
61.
62.
63.
64.
A. Nakao H. Toyokawa A. Tsung M. A. Nalesnik D. B. Stolz J. Kohmoto A. Ikeda K. Tomiyama T. Harada T. Takahashi R. Yang M. P. Fink K. Morita A. M. K. Choi N. Murase 《American journal of transplantation》2006,6(10):2243-2255
Carbon monoxide (CO), a byproduct of heme catalysis, was shown to have potent cytoprotective and anti-inflammatory effects. In vivo recipient CO inhalation at low concentrations prevented ischemia/reperfusion (I/R) injury associated with small intestinal transplantation (SITx). This study examined whether ex vivo delivery of CO in University of Wisconsin (UW) solution could ameliorate intestinal I/R injury. Orthotopic syngenic SITx was performed in Lewis rats after 6 h cold preservation in control UW or UW that was bubbled with CO gas (0.1-5%) (CO-UW). Recipient survival with intestinal grafts preserved in 5%, but not 0.1%, CO-UW improved to 86.7% (13/15) from 53% (9/17) with control UW. At 3 h after SITx, grafts stored in 5% CO-UW showed improved intestinal barrier function, less mucosal denudation and reduced inflammatory mediator upregulation compared to those in control UW. Preservation in CO-UW associated with reduced vascular resistance (end preservation), increased graft cyclic guanosine monophosphate levels (1 h), and improved graft blood flow (1 h). Protective effects of CO-UW were reversed by ODQ, an inhibitor of soluble guanylyl cyclase. In vitro culture experiment also showed better preservation of vascular endothelial cells with CO-UW. The study suggests that ex vivo CO delivery into UW solution would be a simple and innovative therapeutic strategy to prevent transplant-induced I/R injury. 相似文献
65.
66.
The antiepileptic efficacy and tolerability of oxcarbazepine, used both as monotherapy and adjunctive therapy, were observed for 1 year in 202 adult patients, aged 17-83 years, with newly diagnosed or refractory partial epilepsy in clinical practice in Italy. At first observation, the seizure free rate was 72.2% in newly diagnosed patients given monotherapy, 40% in patients in whom oxcarbazepine replaced another monotherapy and 10.3% in patients given oxcarbazepine as adjunctive therapy. At least 50% reduction in seizure frequency was achieved in 90.7, 72 and 57%, respectively. Efficacy increased with the duration of treatment (p < 0.0001). In the 160 completers the seizure free rate was 61.3% with monotherapy and 28% with adjunctive therapy. 16.3% of patients reported adverse effects, mainly sedation and sleepiness; 5% discontinued oxcarbazepine because of adverse events. OXC is an effective and well-tolerated antiepileptic agent for the long-term treatment of partial epilepsy in adults. 相似文献
67.
68.
69.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献
70.